Selective RET Inhibitor Compounds for Resistance and Off-Target Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for RET-related diseases, particularly cancers and irritable bowel syndrome, face challenges due to the development of resistance in tumor cells and the inability of existing kinase inhibitors to selectively target RET wild type and mutants without causing toxicity to other targets, limiting treatment options and efficacy.
Innovation Solution
Development of novel compounds that exhibit selective inhibition of RET kinase, including RET wild type and mutants, with improved properties such as half-life, clearance, selectivity, bioavailability, and chemical stability, to enhance treatment efficacy and reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multi-kinase inhibitors such as Sorafenib, sunitinib, vandetanib and punatinib are used to inhibit RET, then cell proliferation inhibition is achieved in KIF5B-RET-expressing cell lines, but toxicity is caused by inhibition of targets other than RET
Solution Approach 1:
The patent applies local quality by designing a RET kinase inhibitor with a specific molecular structure (Formula I) that provides selective inhibition of RET while avoiding off-target effects. The compound incorporates specific substituents (R1-R6, X1-X5, Z1-Z5) that confer RET selectivity, allowing high efficacy against RET wild type and mutants without the broad-spectrum toxicity of multi-kinase inhibitors.
Solution Approach 2:
The patent employs a single-targeted approach using a specific RET inhibitor compound (Formula I) rather than multi-kinase inhibitors. This single-targeted strategy eliminates the need for multiple kinase targets, thereby avoiding the cumulative toxicity associated with multi-kinase inhibition while maintaining effective RET suppression.
2Reliability
If multi-kinase inhibitors are administered at sufficient levels to inhibit RET, then RET inhibition is improved, but toxicity from other targeted increases
Solution Approach 1:
The patent achieves high RET inhibition levels through a locally optimized molecular structure designed specifically for RET binding. The compound (Formula I) incorporates specific pharmacophores and substituents that enhance RET affinity and selectivity, enabling sufficient inhibition levels without requiring the broad-spectrum activity of multi-kinase inhibitors that causes off-target toxicity.
3Adaptability or versatility
If existing RET inhibitors are used, then treatment is provided for RET-related diseases, but tumor cells develop resistance limiting treatment options
Solution Approach 1:
The patent achieves universality by designing a RET inhibitor (Formula I) that effectively targets both RET wild type and various mutants (including KIF5B-RET fusion proteins). The compound's molecular structure incorporates flexible substituents (R1-R6, X1-X5, Z1-Z5) that allow binding to different RET configurations, providing broad coverage against resistance mechanisms and expanding treatment options for diverse RET-related cancers.
Solution Approach 2:
The patent applies parameter changes by systematically varying molecular parameters (substituents R1-R6, linkers X1-X5, Z1-Z5) to optimize the compound's ability to overcome resistance. The structure allows for tuning binding affinity and selectivity to counteract specific resistance mutations, enabling effective treatment across different resistance profiles.
4Reliability
If novel compounds with improved properties are developed, then treatment efficacy is enhanced and side effects are reduced, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: core scaffold (Formula I), substituent groups (R1-R6), linkers (X1-X5), and terminal groups (Z1-Z5). This modular design allows independent optimization of each segment for specific properties (binding affinity, selectivity, pharmacokinetics) while maintaining overall manageability of the complex molecule through systematic structure-activity relationship analysis.
Data Source
AI summary
Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.